ALNYLAM PHARMACEUTICALS, INC. (ALNY): debt financing — Alnylam issues $661.25M zero-coupon convertible notes due 2028; repurchases $637.8M of existing notes

ALNYLAM PHARMACEUTICALS, INC.

Issued $661.25M aggregate principal of 0.00% Convertible Senior Notes due 2028; initial conversion price $670.11/share (~40% premium).
Capped call transactions entered to offset dilution; cost $35.3M, cap price $837.61/share (~75% premium).
Repurchased $637.8M of existing 1.00% convertible notes due 2027 for ~$1,105.8M total (including accrued interest).
Notes mature Sept 15, 2028, no regular interest; settlement in cash, shares, or combination at Alnylam's election.

item 1.01 item 2.03 item 3.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ALNYLAM PHARMACEUTICALS, INC. incurred convertible notes of $661.25 million with The Bank of New York Mellon at 0.00% maturing September 15, 2028.

Instrument: convertible notes
Principal: $661.25 million
Counterparty: The Bank of New York Mellon
Rate: 0.00%
Maturity: September 15, 2028
Event: incurrence

Exact text from the filing

0.00% Convertible Senior Notes due 2028 (the “Additional Notes” and together with the Initial Notes, the “Notes”), bringing the total aggregate principal amount of the Notes to $661.25 million. The Notes are the Company’s senior unsecured obligations. The Notes were issued pursuant to an Indenture, dated September 12, 2025 (the “Indenture”), between the Company and The

View on SEC.gov

102 debt financings filed in the last 30 days. Browse all debt financings →

ALNYLAM PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-202366

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.